Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Additionally, we ensured that both the non-GLP-1 RA and GLP-1 RA treatment cohorts had similar mean follow-up times (75.9 months, SD = 37.5 and 75.8 months, SD = 37.9, respectively) to control for lead-time bias
Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%
Additionally, this medication works on the GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, triggering several weight loss mechanisms such as appetite suppression, delayed gastric emptying, increased satiety, reduced fat absorption, and increased metabolism
10.3389/fcell.2020.583850 26 CookS.HugliO.EgliM.MenardB.ThalmannS.SartoriC.et al (2004)
